Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2020 Oct 6;6(4):209.
doi: 10.3390/jof6040209.

Isavuconazole-Animal Data and Clinical Data

Livio Pagano  1   2 , Chiara Cattaneo  3 , Martina Quattrone  2 , Margherita Oberti  3 , Maria Mazzitelli  4 , Enrico Maria Trecarichi  4
Affiliations
Review

Isavuconazole-Animal Data and Clinical Data

Livio Pagano et al. J Fungi (Basel). .

Abstract

The treatment of invasive fungal infections has deeply evolved in the last years with the inclusion of new antifungals, mainly new azoles (i.e., posaconazole, isavuconazole), to the therapeutic armamentarium. This review focuses on the role of isavuconazole for treating the most important invasive fungal infections both in animals and humans (hematological and non-hematological patients).

Keywords: Isavuconazole; antifungal prophylaxis; antifungal treatment.

PubMed Disclaimer

Conflict of interest statement

L.P. was a Board member of Gilead Sciences, MSD, Pfizer, Janssen, Novartis, Cidara and has been a speaker for Gilead Sciences, MSD, Pfizer Pharmaceuticals, Astellas. All other authors declared nothing to disclose.

References

    1. Maertens J.A., Raad I.I., Marr K.A., Patterson T.F., Kontoyiannis D.P., Cornely O.A., Bow E.J., Rahav G., Neofytos D., Aoun M., et al. Isavuconazole versus voriconazole for primary treatment of invasive mould disease caused by Aspergillus and other filamentous fungi (SECURE): A phase 3, randomised-controlled, non-inferiority trial. Lancet. 2016;387:360–369. doi: 10.1016/S0140-6736(15)01159-9. - DOI - PubMed
    1. Marty F.M., Ostrosky-Zeichner L., Cornely O.A., Mullane K.M., Perfect J.R., Thompson G.R., Alangaden G.J., Brown J.M., Fredricks D.N., Heinz W.J., et al. Isavuconazole treatment for mucormycosis: A single-arm open-label trial and case-control analysis. Lancet Infect. Dis. 2016;16:828–837. doi: 10.1016/S1473-3099(16)00071-2. - DOI - PubMed
    1. Tissot F., Agrawal S., Pagano L., Petrikkos G., Groll A.H., Skiada A., Lass-Flörl C., Calandra T., Viscoli C., Herbrecht R. ECIL-6 guidelines for the treatment of invasive candidiasis, aspergillosis and mucormycosis in leukemia and hematopoietic stem cell transplant patients. Haematologica. 2017;102:433–444. doi: 10.3324/haematol.2016.152900. - DOI - PMC - PubMed
    1. Ullmann A.J., Aguado J.M., Arikan-Akdagli S., Denning D.W., Groll A.H., Lagrou K., Lass-Flörl C., Lewis R.E., Munoz P., Verweij P.E., et al. Diagnosis and management of Aspergillus diseases: Executive summary of the 2017 ESCMID-ECMM-ERS guideline. Clin. Microbiol. Infect. 2018;24:1–38. doi: 10.1016/j.cmi.2018.01.002. - DOI - PubMed
    1. Cornely O., Alastruey-Izquierdo A., Arenz D., Chen S., Dannaoui E., Hochhegger B., Hoenigl M., Jensen H., Lagrou K., Lewis R., et al. Global guideline for the diagnosis and management of mucormycosis: An initiative of the European Confederation of Medical Mycology in cooperation with the Mycoses Study Group Education and Research Consortium. Lancet Infect Dis. 2019;19:405–421. doi: 10.1016/S1473-3099(19)30312-3. - DOI - PMC - PubMed

LinkOut - more resources